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Performance of T2Candida for detecting intra-abdominal can-
didiasis (IAC) was assessed in 48 high-risk patients. T2Candida 
sensitivity/specificity and positive/negative predictive values 
were 33%/93% and 71%/74%, respectively. IAC was present in 
100% of cases with concordant positive T2Candida/1,3-beta-
d-glucan and absent in 90% of concordant negative results. 
Combination T2Candida/1,3-beta-d-glucan may help guide 
treatment decisions.
Keywords.  invasive candidiasis; candidemia; T2 magnetic 
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Candida spp. frequently cause sepsis and invasive infections in 
intensive care unit (ICU) patients [1]. Intra-abdominal candi-
diasis (IAC), manifesting most often as peritonitis and/or ab-
scesses, is common among ICU patients who have undergone 
complicated abdominal surgery or with other gastrointestinal 
(GI) tract disorders. Blood cultures represent the diagnostic 
gold standard for invasive candidiasis but remain sterile in 
>80% of patients with IAC [2, 3]. Cultures of intra-abdominal 
samples generally are required to diagnose IAC, but they are 
limited by low sensitivity, slow turnaround, and need for inva-
sive procedures. Reliance upon cultures may delay antifungal 
treatment of IAC, which can contribute to high mortality rates 
[2, 3]. Current nonculture diagnostic methods, such as detec-
tion of 1,3-beta-d-glucan (BDG) in serum, identify some pa-
tients with IAC who are missed by cultures. However, serum 
BDG assays are limited by lack of specificity and high false 
positivity [4, 5]. The development and validation of rapid diag-
nostic tests for IAC and other invasive candidiasis are a pressing 
priority.
The T2Candida panel (T2C; T2 Biosystems, Lexington, 
MA, USA) is a fully automated magnetic resonance–based 
molecular test for direct detection of the 5 major pathogenic 
Candida spp. (C.  albicans/C.  tropicalis, C.  glabrata/C.  krusei, 
and C. parapsilosis) in whole-blood samples within 5 hours [6]. 
T2C was cleared by the Food and Drug Administration (FDA) 
and received the “Conformité Européenne” (CE) certification 
for diagnosis of candidemia, based largely on clinical trial data 
demonstrating sensitivity and specificity of ~90% and ~98%, re-
spectively, for detecting target Candida spp. [7, 8]. Data on T2C 
performance for diagnosis of noncandidemic invasive candidi-
asis, such as IAC, are scant [9]. Our objective was to assess the 
performance of T2C for detection of IAC compared with blood 
cultures and BDG testing.
METHODS
Cases were included from a previous prospective cohort study 
by the Fungal Infection Network of Switzerland (FUNGINOS) 
[5]. Adults (≥18 years old) in ICUs of 2 university hospitals were 
enrolled consecutively if they exhibited the following risk factors 
for IAC: (i) recurrent GI tract perforation (anastomotic leakage 
or recurrent surgical transection of the gut), (ii) acute necro-
tizing pancreatitis (Balthazar grade D-E), or (iii) recent abdom-
inal surgery (<3  days) and Candida colonization of nonsterile 
sites (eg, mouth, urine, stool, skin, or respiratory tract). A di-
agnosis of IAC was established if a Candida spp. was isolated by 
perioperative intra-abdominal culture, as previously described 
[5]. Blood cultures (2 sets of BACTEC Plus aerobic/F and Lytic 
anaerobic/F bottles, Becton Dickinson, Sparks, MD, USA) were 
performed in cases of fever or clinical suspicion of infection. 
Blood and serum samples were collected twice weekly from in-
clusion until 2 weeks after ICU discharge. Sera underwent BDG 
testing (Fungitell, Associates of Cape Cod, Falmouth, MA, USA; 
positivity cutoff ≥80 pg/mL) as part of the previous study [5]. 
T2C testing was performed on archived frozen blood samples 
that were thawed and in which sufficient volume was available 
(≥3 mL). Samples collected within 72 hours of IAC diagnosis, or 
between days 7 and 10 from study inclusion for patients without 
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IAC, were analyzed. Performance of T2C for the diagnosis of 
IAC was compared with that of BDG and blood cultures.
This study was approved by the local ethics committee, and 
written informed consent was obtained from patients or their 
legal representatives [5].
RESULTS
Valid T2C results were obtained for 48 ICU patients who were at 
risk for IAC, including 18 patients with IAC and 30 patients who 
did not fulfill IAC criteria as defined above. The clinical charac-
teristics of the patients are presented in the Supplementary Data 
(Supplementary Table 1).
C. albicans was the causative agent of IAC in 72% (13/18) of 
patients. C. tropicalis (n = 2), Candida spp. not included in the 
T2C panel (C. kefyr, C. lusitaniae), and C. albicans/C. glabrata 
(n  =  1) were involved in the remaining cases. Eleven percent 
(2/18) of patients with IAC were diagnosed with candidemia 
by blood culture. T2C was positive in 33% (6/18) of IAC pa-
tients, including the 2 patients with candidemia. Candida spp. 
detected by T2C matched those from intra-abdominal cultures. 
Eleven percent (2/18) of patients had been receiving antifungal 
treatment for 4 days at the time of IAC diagnosis; T2C was neg-
ative in these patients. T2C was negative in 93% (28/30) of pa-
tients without IAC. The 2 patients in whom T2C was positive 
had negative BDG results in follow-up samples despite Candida 
colonization at multiple sites, did not receive antifungal therapy, 
and survived until hospital discharge.
Per-patient sensitivity, specificity, positive and negative 
predictive values (PPV and NPV), and positive and negative 
likelihood ratios for T2C and BDG are provided in Table  1. 
Concordant positive T2C/BDG results were associated with 
IAC in 100% (5/5) of patients. Concordant negative results 
were associated with absence of IAC in 90% (18/20) of patients. 
Discordant T2C and BDG results were observed in 48% (23/48) 
of patients, 48% (11/23) of whom had IAC.
DISCUSSION
To our knowledge, this is the first study to determine T2C per-
formance specifically for the diagnosis of IAC. T2C sensitivity 
and specificity were 33% and 93%, respectively. Our findings 
are in keeping with those reported recently in a study from 2 
ICUs in Denmark, in which T2C sensitivity and specificity for 
proven or likely noncandidemic invasive candidiasis (including 
a limited number with IAC, n = 6) were 45% and 96%, respec-
tively [9]. Similar to the Danish study, our analysis demon-
strated the ability of T2C to detect noncandidemic deep-seated 
invasive candidiasis.
The performance of T2C in diagnosing IAC, marked by high 
specificity and PPV, stands in contrast to that reported previ-
ously for serum BDG. In previous studies, BDG sensitivity 
and specificity for IAC ranged from 53% to 77% and 55% to 
78%, respectively [5, 10–12]. The relative strengths of BDG for 
diagnosing IAC compared with T2C are improved sensitivity 
and excellent NPV. The complementary performance charac-
teristics of T2C and BDG suggest that the tests might have the 
greatest clinical utility when used in combination. Indeed, con-
cordant positive T2C and BDG results indicated IAC in 100% 
of cases, and concordant negative results could reliably exclude 
IAC in 90% of cases. The probability of IAC if 1 test was positive 
and the other was negative was 48%, which is likely sufficient to 
justify antifungal therapy in at-risk patients with signs of intra-
abdominal infection in whom an alternative diagnosis is not 
apparent. For these patients, the need for ongoing antifungal 
therapy should be reassessed based on clinical evolution and 
microbiological results.
This study was limited by its small size and retrospective 
design. Use of freeze-thaw archived samples may account for 
the high rate of invalid T2C results (31%), which exceeded 
7.6% and 9.2% for freshly collected and freeze-thawed sam-
ples, respectively, in clinical trials [7, 8]. A potential explana-
tion for these findings is that the frozen samples were stored 
for several years, following their original collection during the 
FUNGINOS study. Indeed, even for samples giving putatively 
“valid” negative results, it is possible that test performance was 
impacted. The influence of antifungal therapy on T2C perfor-
mance for diagnosing IAC remains unclear. Although only 11% 
of our patients were receiving an antifungal drug at the time of 
T2C testing, the corresponding figure was 77% among subjects 
in the Danish ICU study [9]. The low yield of blood cultures for 
IAC detection in the present study is comparable to that pre-
viously reported [2, 3]. Only standard blood cultures (aerobic 
and anaerobic vials) were used. It is unclear if the use of specific 
fungal culture vials increases the performance of blood culture 
for detection of candidemia [13].
T2C may have generated false-positive results in 2 patients 
who did not have clinical evidence of invasive candidiasis and 
in whom outcomes were favorable in the absence of antifungal 
therapy. However, we cannot exclude that T2C may have de-
tected transient candidemia in these patients that was not 
diagnosed by blood cultures. Finally, in our study, 11% (2/18) 
of IAC was attributed to Candida species not included in the 
Table 1. Performance of T2Candida and 1,3-Beta-D-Glucan for Detection 
of Intra-abdominal Candidiasis
T2Candida 1,3-Beta-D-Glucan
Sensitivity, 33.3 (13.3–59.0) 83.3 (58.6–96.4)
Specificity, % 93.3 (77.9–99.2) 66.7 (47.2–82.7)
Positive predictive value,a % 71.1 (35.7–91.6) 55.2 (41.6–68.0)
Negative predictive value,a % 74.0 (66.9–80.0) 89.0 (73.7–95.9)
Positive likelihood ratio 5.00 (1.13–22.18) 2.50 (1.45–4.32)
Negative likelihood ratio 0.71 (0.51–1.00) 0.25 (0.09–0.72)
Values in brackets are 95% confidence intervals.
aCalculated for a disease prevalence of 33% in the original prospective cohort study [5].
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T2C panel. The fact that the spectrum of detection of T2C is 
restricted to 5 Candida species is an intrinsic limitation of the 
test. These 5 species account for ≥95% of invasive candidiasis 
at most centers, but local epidemiology must be taken into ac-
count in determining the value of the panel at each hospital [7]. 
At present, T2C does not detect emerging Candida auris, which 
has been involved in nosocomial outbreaks. A research proto-
type T2C assay including this species has sensitivity and spec-
ificity comparable to those reported for the current panel [14].
In conclusion, T2C may detect at least some cases of 
noncandidemic IAC. Moreover, combination T2C/BDG testing 
may be useful in defining the probability of IAC as high (approaching 
100%), moderate (~50%), or low (≤10%) based on concordant 
positive, discordant, and concordant negative results, respectively. 
Follow-up investigations of T2C in diagnosing IAC and other types 
of invasive candidiasis using freshly collected samples are needed, 
as are studies of the impact of T2C- and BDG-guided treatment on 
patient outcomes, antifungal stewardship, and hospital costs.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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